Advanced search
Publication Cover
Research and Reports in Urology Volume 13, 2021 - Issue
Submit an article Journal homepage
139
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Significance of PSA Screening in Niigata, Japan: Survey of Actual Status of New Cases of Prostate Cancer

Toshihiro Saito1 Department of Urology, Niigata Cancer Center Hospital, Niigata, JapanCorrespondence[email protected]
,
Shuichi Komatsubara2 Department of Urology, Niigata Minami Hospital, Niigata, Japan
,
Noboru Hara3 Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan
,
Tsutomu Nishiyama3 Department of Urology, Uonuma Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Japan
,
Akiyoshi Katagiri4 Department of Urology, Niigata Prefectural Central Hospital, Joetsu, Japan
,
Fumio Ishizaki5 Department of Renal and Urinary Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
,
Akihiko Hatano6 Department of Urology, Niigata Prefectural Shibata Hospital, Shibata, Japan
,
Takeshi Komeyama7 Department of Urology, Nagaoka Red Cross Hospital, Nagaoka, Japan
,
Shugo Hanyu8 Department of Urology, Kashiwazaki General Hospital and Medical Center, Kashiwazaki, Japan
,
Masahiro Terunuma9 Department of Urology, Nagaoka Chuo General Hospital, Nagaoka, Japan
,
Tomoyuki Imai10 Department of Urology, Niigata City General Hospital, Niigata, Japan
,
Hideto Go11 Department of Urology, Niigata Saiseikai Sanjo Hospital, Sanjo, Japan
,
Hiroaki Iida12 Department of Urology, Joetsu General Hospital, Joetsu, Japan
,
Shigenori Kurumada13 Department of Urology, Saiseikai Niigata Hospital, Niigata, Japan
,
Shunsuke Yamaguchi4 Department of Urology, Niigata Prefectural Central Hospital, Joetsu, Japan;14 Department of Urology, Tachikawa General Hospital, Nagaoka, Japan
,
Keisuke Takeda5 Department of Renal and Urinary Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan;15 Department of Urology, Murakami General Hospital, Murakami, Japan
,
Takashi Ando14 Department of Urology, Tachikawa General Hospital, Nagaoka, Japan;15 Department of Urology, Murakami General Hospital, Murakami, Japan
,
Tatsuhiko Hoshii5 Department of Renal and Urinary Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
,
Takashi Kasahara5 Department of Renal and Urinary Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
&
Yoshihiko Tomita5 Department of Renal and Urinary Pathology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan
 show all
Pages 859-866 | Published online: 24 Dec 2021

References

  • Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T. Japanese guideline for prostate cancer screening. Jpn J Clin Oncol. 2009;39:339–351. doi:10.1093/jjco/hyp025
  • Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384:2027–2035. doi:10.1016/S0140-6736(14)60525-0
  • Hugosson J, Roobol MJ, Månsson M, et al. ERSPC investigators: a 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76:43–51. doi:10.1016/j.eururo.2019.02.009
  • Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomized population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725–732. doi:10.1016/S1470-2045(10)70146-7
  • Oberaigner W, Siebert U, Horninger W, et al. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health. 2012;57:57–62. doi:10.1007/s00038-011-0266-4
  • The Japanese Urological Association. Screening guideline for prostate cancer Medical View. Tokyo, Japan. 2018. Japanese.
  • Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319. doi:10.1056/NEJMoa0810696
  • Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123:592–599. doi:10.1002/cncr.30474
  • Ito K, Oki R, Sekine Y, et al. Screening for prostate cancer: history, evidence, controversies and future perspectives toward individualized screening. Int J Urol. 2019;26:956–970. doi:10.1111/iju.14039
  • Komatsubara S, Nishiyama T, Katagiri A, et al. [Screening of prostate cancer in Niigata prefecture]. J Niigata Med Assoc. 2015;786:6–10. Japanese.
  • Niigata Prefectural Government. Results of prostate cancer screening; 2021. Available from: https://www.kenko-niigata.com/material/files/group/4/01_g_zenritsusengan.xlsx. Accessed November 15, 2021. Japanese.
  • Aragona F, Pepe P, Motta M, et al. Incidence of prostate cancer in Sicily: results of a multicenter case-findings protocol. Eur Urol. 2005;47:569–574. doi:10.1016/j.eururo.2004.11.007
  • Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity —United States, 2001–2017. MMWR Morb Mortal Wkly Rep. 2020;69:1473–1480. doi:10.15585/mmwr.mm6941a1
  • National Cancer Center Japan, Center for Cancer Control and Information Services. Cancer registry at cancer medical care cooperation base hospitals 2019 national report; 2021. Available from: https://ganjoho.jp/public/qa_links/report/hosp_c/pdf/2019_report.pdf. Accessed November 15, 2021. Japanese.
  • Kitagawa Y, Namiki M. Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J Androl. 2015;17:475–480. doi:10.4103/1008-682X.143756
  • Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137:1749–1757. doi:10.1002/ijc.29538
  • Bul M, Zhu X, Valdagni RT, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013;63:597–603. doi:10.1016/j.eururo.2012.11.005
  • Mitsuzuka K, Koga H, Sugimoto M, et al. Current use of active surveillance for localized prostate cancer: a nationwide survey in Japan. Int J Urol. 2015;22:754–759. doi:10.1111/iju.12813
  • Kato T, Sugimoto M. Quality of life in active surveillance for early prostate cancer. Int J Urol. 2020;27:296–306. doi:10.1111/iju.14202
  • Pepe P, Garufi A, Priolo GD, et al. Is it time to perform only magnetic resonance imaging targeted cores? Our experience with 1032 men who underwent prostate biopsy. J Urol. 2018;200:774–778. doi:10.1016/j.juro.2018.04.061
  • Grossman DC, Curry SJ, Owens DK, et al. Screening for prostate cancer: US preventive services task force recommendation statement. JAMA. 2018;319:1901–1913. doi:10.1001/jama.2018.3710

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.